Search

The reference design is described for the first Quadrupole magnet at TJNAF's Super High Momentum Spectrometer (SHMS) (Q1). The magneto-static solver is used for modeling the magnetic performance as well as the forces and store energy calculations.

The use of superconducting magnets in ECR ion sources has the potential for large power savings compared with resistive magnets. Space Cryomagnetics Ltd has designed a High Temperature superconducting magnets having the potential for large power saving.

The Alpha Magnetic Spectrometer (AMS) isa particle physics experiment based on the International Space Station (ISS). At the heart of the detector is a large superconducting magnet, cooled to a temperature of 1.8 K by superfluid helium. The magnet and cryogenic system have been designed and built by Scientific Magnetics (formerly Space Cryomagnetics) of Culham, England. This paper describes the results from magnet testing, and the final assembly of the magnet and flight cryostat. [ABSTRACT FROM AUTHOR]

Trial Coil winding of full size coils for the Qi magnet of the Super High Momentum Spectrometer (SHMS) for JLAB Hall C has been performed under contract by Scientific Magnets Inc. This effort was required to demonstrate that the unique Qi Cold Iron Quadrupole shape can be executed with a Rutherford type SC cable. Details of the prototype winding tooling, conductor insulation scheme, coil former, the winding process including clamping and curing will be presented. Lessons learned from the initial set of windings were incorporated into the final trail windings of two complete full scale coils that can potentially be used in the actual magnet fabrication. The initial trial windings indicted that the coil end turns would benefit from additional support in the winding form and inclusion of a 5 degree shim along the first turn of the coil would be helpful in improving the fit up of the coils on the symmetry planes, leading to an improved end shape. These changes in coil shape were modeled in TOSCA and the resultant magnetic properties confirmed. The Qi coils wound were tested for electrical properties, insulation effectiveness and dimensional consistency. Results from the three coils wound wilt be presented. [ABSTRACT FROM AUTHOR]

The reference design for the first Quadrupole magnet of TJNAF's Super High Momentum Spectrometer (SHMS), Q1, is presented. The SHMS is a DQQQD design that will be capable of resolving particles up to 11 Gev/c in momentum. Q1 follows the successful design of the High Momentum Spectrometer's (HMS) Q1, that of an elliptically shaped super ferric yoke, conformal mapped window frame coil, and helium bath cooled coil design. The primary differences between the two designs is in the choice of superconducting cable and an overall longer magnet length. A single stack of surplus SSC Rutherford NbTi cable replaces the original four stack copper stabilized conductor used in the HMS's Q1. The SHMS Q1 will have a warm bore diameter of 400 mm and produce field gradients tip to 9.1 T/m with an effective length of 2.14 m. Test coil windings progress will be given as well as reports on forces, conductor stability and energy margins. [ABSTRACT FROM AUTHOR]

Ion sources using electron cyclotron resonance (ECR) require magnets to generate a particular field profile. High temperature superconducting (HTS) magnets offer advantages in power density, efficiency and the overall simplicity of the system. Space Cryomagnetics Ltd of Culham, England, has designed and manufactured HTS magnets for an ion source for Pantechnik in France, and is currently developing a second, more powerful system for the Laboratoire de Physique Subatomique et de Cosmologie (LPSC) in Grenoble, France. This paper describes the design, manufacture and test results of the first of these systems, and the current status of the design and manufacture of the second. [ABSTRACT FROM AUTHOR]

The Alpha Magnetic Spectrometer (AMS) is a particle physics experiment based on the International Space Station (ISS). At the heart of the detector is a large superconducting magnet, cooled to a temperature of 1.8 K by superfluid helium. The magnet and cryogenic system are currently under construction by Space Cryomagnetics Ltd of Culham, England. This paper describes the current status of the design and manufacture of the magnet system-including test results from the fourteen superconducting coils-and outlines the remaining work required to complete the project. [ABSTRACT FROM AUTHOR]

The use of superconducting magnets in ECR ion sources has the potential for large power savings compared with resistive magnets. High temperature superconductors (HTS) offer further advantages including compactness, efficiency, and a simplification of the overall system. Space Cryomagnetics Ltd has designed and manufactured a pair of HTS magnets for an ion source for Pantechnik. In this paper we describe the design, manufacture, and test results of these magnets. [ABSTRACT FROM AUTHOR]

The proposed European Space Agency (ESA) XEUS mission will use an adiabatic demagnetization refrigeration (ADR) system to cool X-ray detectors to a temperature of less than 0.1 K. The superconducting magnet for the flight standard prototype is currently under construction by Space Cryomagnetics Ltd of Culham, England. The magnet is subject to tight constraints on its mass, stray field, and power consumption. This paper describes the design, manufacture and test of the magnet. [ABSTRACT FROM AUTHOR]

Introduction: Health research bodies recommend patient involvement and engagement in research and healthcare planning, although their implementation is not yet widespread. This deficiency extends to progressive pulmonary fibrosis (PPF), where crucial aspects remain unknown, including causal mechanisms, curative treatments and optimal symptom management. This study addresses these gaps by seeking stakeholders' perspectives to guide research and treatment directions., Method: A priority-setting partnership was established to explore stakeholders' priorities in the diagnosis, treatment, management and care of PPF, including idiopathic pulmonary fibrosis which is the archetypal PPF. Stakeholders included people living with PPF, their carers, relatives and healthcare professionals involved in their management., Results: Through an online open-ended survey, 2542 responses were collected from 638 stakeholders. Thematic analysis identified 48 specific research questions, which were then cross-referenced with academic literature to pinpoint research gaps. Following the evidence check, 44 unanswered questions were shortlisted by 834 stakeholders in a second online survey. Ultimately, a top 10 priority list was established through consensus.The prioritised research questions include (1) improved diagnosis accuracy and timing, (2) development of new treatments, (3) enhanced accuracy in primary care, (4) optimal timing for drug and non-drug interventions, (5) effective cough treatment, (6) early intervention for PPF, (7) improved survival rates, (8) symptom reduction, (9) impact of interventions on life expectancy and (10) new treatments with reduced side effects., Conclusion: Stakeholders' priorities can be summarised into five areas: early diagnosis, drug and non-drug treatments, survival and symptom management. Ideally, these topics should guide funding bodies and health policies., Competing Interests: Competing interests: AMR discloses payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Hoffman La Roche, Irish Lung Fibrosis Association, Aerogen. Support for attending meetings and travel from Boehringer Ingelheim, Hoffman La Roche, Interstitial Lung Disease Interdisciplinary Network. GJ discloses grants or contracts from any entity from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, Nordic Biosciences, RedX, Pliant; consulting fees from Apollo Therapeutics, AstraZeneca, Brainomix. Bristol Myers Squibb, Chiesi, Cohbar, Daewoong, GlaxoSmithKline, Veracyte, Resolution Therapeutics, Pliant; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Chiesi, Roche, PatientMPower, AstraZeneca; payment for expert testimony from Pinsent Masons; participation on a Data Safety Monitoring Board or Advisory Board with Boehringer Ingelheim, Galapagos, Vicore; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with NuMedii and Action for Pulmonary Fibrosis., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)